MiR-221 affects the proliferation and apoptosis of laryngeal cancer cells through the PI3K/AKT signaling pathway

OBJECTIVE

To investigate the effect of MiR-221 on proliferation and apoptosis of laryngeal carcinoma cells through the PI3K/AKT signaling pathway.

MATERIALS AND METHODS

LipofectamineTM 2000 liposomes were used to transfer MiR-221 analogue, MiR-221 NC into Hep-2 cells of laryngeal carcinoma. Real-time fluorescence quantitative polymerase chain reaction (PCR) method was used to detect the expression of MiR-221, MTT method was used to detect the proliferation of cells, flow cytometry was used to detect cell cycle, Western blotting was used to detect the expression of apoptosis proteinase-1 (Apaf-1) and cyclin-dependent kinase (CDK1, CDK2) protein and the activation of phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT).

RESULTS

Compared with MiR-221 NC group, the expression of MiR-221 in MiR-221 analogue group was up-regulated (p<0.01), the cell proliferation rate was decreased (p<0.01), the cell cycle was stagnated in the G1 phase (p<0.01), the expression levels of Cyclin A, CDK1, CDK2, PI3K, and p-AKT were significantly down-regulated (p<0.01), and the expression levels of Bax and Apaf-1 were significantly up-regulated (p<0.01).

CONCLUSIONS

MiR-221 analogues can significantly inhibit the proliferation and induce apoptosis of Hep-2 cells in laryngeal cancer, and this is achieved by blocking the PI3K/AKT signaling pathway, which also indicates that MiR-221 affects the proliferation and apoptosis of laryngeal cancer cells through the PI3K/AKT signaling pathway.

[Management of toxicities associated with pegaspargase in treatment of patients with lymphoid malignancy: experience from 443 cases in a single center]

目的

总结培门冬酶治疗淋巴系统肿瘤的不良反应以及处理经验。

方法

通过回顾性分析北京同仁医院血液科2011年8月至2015年12月使用培门冬酶患者的临床资料，总结培门冬酶相关的不良反应以及处理经验。

结果

129例患者使用培门冬酶，累计共使用443例次，不良反应发生情况：2例（1.6%）患者出现过敏反应；19例（14.7%）患者发生胰腺炎（其中包括6例急性症状性胰腺炎、13例单纯胰酶升高的化学性胰腺炎），15例（11.6%）患者出现高甘油三酯血症，85例（65.9%）患者出现高血糖，7例（5.4%）患者出现低血糖；25例（19.4%）患者出现2级以上的转氨酶增高，21例（15.5%）患者发生高胆红素血症，62例（48.1%）患者发生低白蛋白血症；61例（47.3%）患者出现APTT延长，22例（17.1%）患者出现PT延长，15例（11.6%）患者出现TT延长，75例（58.1%）患者出现低纤维蛋白原血症，有11例患者（8.5%）出现血栓事件，有3例（2.3%）患者出现活动性出血。以上不良反应，分别经过抗过敏、抑制胰液分泌、降脂、降糖、保肝、补充血浆、止血等对症治疗后症状均好转。部分严重不良反应影响培门冬酶的按计划应用甚至导致停用。

结论

培门冬酶的不良反应非常广泛，有些非常严重，需要治疗时密切监测。

CT diagnosis of renal vein thrombosis in nephrotic syndrome

Forty-seven patients with nephrotic syndrome were prospectively studied for renal vein (RVT) and inferior vena caval (IVCT) thrombosis with dynamic CT. Renal venography and inferior vena cavography was performed on the 12 patients with and on 5 of the patients without CT evidence of thrombosis. Dynamic CT revealed thrombi in 12 of 47 (26%) of the cases (RVT in 8, IVCT in 5); all were confirmed by venography. In one of the cases with RVT, a thrombus in a superior branch of the left renal vein was revealed by venography but not by CT. Venography was normal in all five patients evaluated with normal dynamic CT. We believe that dynamic CT can be used to effectively examine patients with suspected RVT.